ImmunityBio (IBRX) Cash from Financing Activities (2014 - 2026)
ImmunityBio (IBRX) reported Cash from Financing Activities of $223.9 million for Q1 2026, up 22903.05% year-over-year from N/an in Q1 2025, and up 307.92% on a QoQ basis from $54.9 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Cash from Financing Activities data on file, last reported at $223.9 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 22903.05% year-over-year to $223.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $625.1 million (up 131.17% YoY) and the FY2025 annual result came in at $400.2 million, up 42.12% from the prior year.
- Cash from Financing Activities advanced to $223.9 million in Q1 2026 per IBRX's latest filing, from $54.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $237.5 million in Q3 2023 and bottomed at -$982000.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is $106.9 million (2024), against an average of $99.9 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities soared 289513.33%; it then plunged 109.6% in 2025.
- Tracing IBRX's Cash from Financing Activities over 5 years: stood at $109.9 million in 2022, then surged by 82.41% to $200.5 million in 2023, then tumbled by 46.68% to $106.9 million in 2024, then slumped by 48.66% to $54.9 million in 2025, then jumped by 307.92% to $223.9 million in 2026.
- Per Business Quant, the three latest IBRX Cash from Financing Activities figures stand at $223.9 million (Q1 2026), $54.9 million (Q4 2025), and $173.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 223.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 223.93 Mn |
| Mar 31, 2026 | 223.93 Mn |
| Dec 31, 2025 | 54.89 Mn |
| Dec 31, 2025 | 54.89 Mn |
| Sep 30, 2025 | 173.52 Mn |
| Sep 30, 2025 | 173.52 Mn |
| Jun 30, 2025 | 172.81 Mn |
| Jun 30, 2025 | 172.81 Mn |
| Mar 31, 2025 | -982,000.00 |
| Mar 31, 2025 | -982,000.00 |
| Dec 31, 2024 | 106.93 Mn |
| Dec 31, 2024 | 106.93 Mn |
| Sep 30, 2024 | 15.58 Mn |
| Sep 30, 2024 | 15.58 Mn |
| Jun 30, 2024 | 148.89 Mn |
| Jun 30, 2024 | 148.89 Mn |
| Mar 31, 2024 | 10.23 Mn |
| Mar 31, 2024 | 10.23 Mn |
| Dec 31, 2023 | 200.54 Mn |
| Dec 31, 2023 | 200.54 Mn |
| Sep 30, 2023 | 237.50 Mn |
| Sep 30, 2023 | 237.50 Mn |
| Jun 30, 2023 | 43.41 Mn |
| Jun 30, 2023 | 43.41 Mn |
| Mar 31, 2023 | 76.89 Mn |
| Mar 31, 2023 | 76.89 Mn |
| Dec 31, 2022 | 109.94 Mn |
| Dec 31, 2022 | 109.94 Mn |
| Sep 30, 2022 | 123.99 Mn |
| Sep 30, 2022 | 123.99 Mn |
| Jun 30, 2022 | -15,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -298,000.00 |
| Mar 31, 2022 | -298,000.00 |
| Dec 31, 2021 | 325.95 Mn |
| Dec 31, 2021 | 325.95 Mn |
| Sep 30, 2021 | 42.66 Mn |
| Sep 30, 2021 | 42.66 Mn |
| Jun 30, 2021 | 98.34 Mn |
| Jun 30, 2021 | 98.34 Mn |
| Mar 31, 2021 | 38.50 Mn |
| Mar 31, 2021 | 38.50 Mn |
| Dec 31, 2020 | 241,000.00 |
| Dec 31, 2020 | 241,000.00 |
| Sep 30, 2020 | 63.22 Mn |
| Sep 30, 2020 | 63.22 Mn |
| Jun 30, 2020 | 87.34 Mn |
| Jun 30, 2020 | 87.34 Mn |
| Mar 31, 2020 | -123,000.00 |
| Mar 31, 2020 | -123,000.00 |
| Dec 31, 2019 | 75.63 Mn |
| Dec 31, 2019 | 75.63 Mn |
| Sep 30, 2019 | -40,000.00 |
| Sep 30, 2019 | -40,000.00 |
| Jun 30, 2019 | -501,000.00 |
| Jun 30, 2019 | -501,000.00 |
| Mar 31, 2019 | 39.20 Mn |
| Mar 31, 2019 | 39.20 Mn |
| Dec 31, 2018 | -370,000.00 |
| Dec 31, 2018 | -370,000.00 |
| Sep 30, 2018 | -115,000.00 |
| Sep 30, 2018 | -115,000.00 |
| Jun 30, 2018 | -201,000.00 |
| Jun 30, 2018 | -201,000.00 |
| Mar 31, 2018 | -85,000.00 |
| Mar 31, 2018 | -85,000.00 |
| Dec 31, 2017 | -3.14 Mn |
| Dec 31, 2017 | -3.14 Mn |
| Sep 30, 2017 | -14.95 Mn |
| Sep 30, 2017 | -14.95 Mn |
| Jun 30, 2017 | -16.43 Mn |
| Jun 30, 2017 | -16.43 Mn |
| Mar 31, 2017 | -468,000.00 |
| Mar 31, 2017 | -468,000.00 |
| Dec 31, 2016 | -4.10 Mn |
| Dec 31, 2016 | -4.10 Mn |
| Sep 30, 2016 | -2.99 Mn |
| Sep 30, 2016 | -2.99 Mn |
| Jun 30, 2016 | -6.58 Mn |
| Jun 30, 2016 | -6.58 Mn |
| Mar 31, 2016 | -1.89 Mn |
| Mar 31, 2016 | -1.89 Mn |
| Dec 31, 2015 | 306,000.00 |
| Dec 31, 2015 | 306,000.00 |
| Sep 30, 2015 | 243.08 Mn |
| Sep 30, 2015 | 243.08 Mn |
| Jun 30, 2015 | 73.97 Mn |
| Jun 30, 2015 | 73.97 Mn |
| Mar 31, 2015 | -22,000.00 |
| Mar 31, 2015 | -22,000.00 |
| Dec 31, 2014 | 58.53 Mn |
| Dec 31, 2014 | 58.53 Mn |
| Sep 30, 2014 | 127,000.00 |
| Sep 30, 2014 | 127,000.00 |